Paul Burton - Jun 16, 2022 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role
Chief Medical Officer
Signature
/s/ Brian Sandstrom, as Attorney-in-Fact
Stock symbol
MRNA
Transactions as of
Jun 16, 2022
Transactions value $
$0
Form type
4
Date filed
6/21/2022, 04:03 PM
Previous filing
Mar 3, 2022
Next filing
Aug 9, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRNA Stock Option (Right to Buy) Award $0 +6.9K $0.00 6.9K Jun 16, 2022 Common Stock 6.9K $121.08 Direct F1
transaction MRNA Restricted Stock Units Award $0 +3.66K $0.00 3.66K Jun 16, 2022 Common Stock 3.66K $0.00 Direct F2
transaction MRNA Stock Option (Right to Buy) Award $0 +19.8K $0.00 19.8K Jun 16, 2022 Common Stock 19.8K $121.08 Direct F3
transaction MRNA Restricted Stock Units Award $0 +11K $0.00 11K Jun 16, 2022 Common Stock 11K $0.00 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of this option will vest and become exercisable on June 16, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
F2 25% of the shares subject to this restricted stock unit award will vest on June 16, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
F3 50% of this option will vest and become exercisable on June 16, 2025 and the remaining 50% will vest and become exercisable on June 16, 2026, subject to the recipient's continued service.
F4 50% of the shares subject to this restricted stock unit award will vest on June 16, 2025 and the remaining 50% will vest on June 16, 2026, subject to the recipient's continued service.